- Home
- ELEV vs XAIR Comparison
ELEV vs XAIR Comparison
Compare ELEV & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELEV
- XAIR
- Stock Information
- Founded
- ELEV 2019
- XAIR 2011
- Country
- ELEV United States
- XAIR United States
- Employees
- ELEV N/A
- XAIR N/A
- Industry
- ELEV Biotechnology: Pharmaceutical Preparations
- XAIR Medical/Dental Instruments
- Sector
- ELEV Health Care
- XAIR Health Care
- Exchange
- ELEV Nasdaq
- XAIR Nasdaq
- Market Cap
- ELEV 34.0M
- XAIR 34.7M
- IPO Year
- ELEV 2021
- XAIR N/A
- Fundamental
- Price
- ELEV $0.61
- XAIR $0.52
- Analyst Decision
- ELEV Strong Buy
- XAIR Strong Buy
- Analyst Count
- ELEV 5
- XAIR 4
- Target Price
- ELEV $7.80
- XAIR $3.67
- AVG Volume (30 Days)
- ELEV 673.9K
- XAIR 617.0K
- Earning Date
- ELEV 11-06-2024
- XAIR 11-11-2024
- Dividend Yield
- ELEV N/A
- XAIR N/A
- EPS Growth
- ELEV N/A
- XAIR N/A
- EPS
- ELEV N/A
- XAIR N/A
- Revenue
- ELEV N/A
- XAIR $2,342,000.00
- Revenue This Year
- ELEV N/A
- XAIR $640.47
- Revenue Next Year
- ELEV N/A
- XAIR $286.81
- P/E Ratio
- ELEV N/A
- XAIR N/A
- Revenue Growth
- ELEV N/A
- XAIR 685.91
- 52 Week Low
- ELEV $0.44
- XAIR $0.30
- 52 Week High
- ELEV $5.83
- XAIR $2.36
- Technical
- Relative Strength Index (RSI)
- ELEV 51.53
- XAIR 56.95
- Support Level
- ELEV $0.52
- XAIR $0.49
- Resistance Level
- ELEV $0.70
- XAIR $0.54
- Average True Range (ATR)
- ELEV 0.06
- XAIR 0.05
- MACD
- ELEV 0.00
- XAIR -0.00
- Stochastic Oscillator
- ELEV 41.81
- XAIR 70.51
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.
About XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.